Tuberculosis detection kit PC2022010116

for mycobacterialaboratorytissue

The incidence rate of lung diseases is increasing year by year, especially the high incidence of pulmonary infectious diseases and lung tumors, which seriously threaten human health and life safety. At present, lung biopsy and lung tissue samples are often performed only by pathological examination. Although pathological examination can identify most of the benign and malignant lesions, it is seldom applied to the diagnosis of infectious diseases. Clinical microbiological examination plays an indispensable role in infectious diseases diagnosis, medication guidance, hospital infection control, antimicrobial management etc. However, this field still faces major problems such as long sample circulation time. For example, in terms of microbial identification, although there are automatic calibrators, which relatively shortens the time, they are mostly based on the principle of microbial biochemical reaction, and still cannot achieve rapid identification. Therefore, clinical microbiology laboratory urgently needs new testing technology to replace the existing technology and achieve new breakthroughs. DETECTION METHOD Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) technology is used to extract nucleic acids from patients' lung tissues. DNA detection technology combined with PCR in vitro amplification and massarray mass spectrometry are used to qualitatively detect the extracted nucleic acids to identify some pathogenic mycobacteria and their subtypes and confirm whether the patient is infected with the microorganism to be tested.